QQQ   293.62 (+0.09%)
AAPL   148.20 (+0.11%)
MSFT   254.74 (-0.16%)
META   120.16 (+1.74%)
GOOGL   101.18 (+0.19%)
AMZN   95.75 (-0.82%)
TSLA   195.18 (+0.25%)
NVDA   171.89 (+1.57%)
NIO   12.23 (-4.30%)
BABA   86.05 (-1.72%)
AMD   76.97 (-0.85%)
T   19.13 (-0.78%)
MU   55.49 (-3.75%)
CGC   3.75 (+3.59%)
F   14.03 (+0.94%)
GE   85.43 (-0.63%)
DIS   97.97 (+0.10%)
AMC   8.68 (+20.06%)
PYPL   78.41 (+0.00%)
PFE   50.85 (+1.44%)
NFLX   317.14 (+3.80%)
QQQ   293.62 (+0.09%)
AAPL   148.20 (+0.11%)
MSFT   254.74 (-0.16%)
META   120.16 (+1.74%)
GOOGL   101.18 (+0.19%)
AMZN   95.75 (-0.82%)
TSLA   195.18 (+0.25%)
NVDA   171.89 (+1.57%)
NIO   12.23 (-4.30%)
BABA   86.05 (-1.72%)
AMD   76.97 (-0.85%)
T   19.13 (-0.78%)
MU   55.49 (-3.75%)
CGC   3.75 (+3.59%)
F   14.03 (+0.94%)
GE   85.43 (-0.63%)
DIS   97.97 (+0.10%)
AMC   8.68 (+20.06%)
PYPL   78.41 (+0.00%)
PFE   50.85 (+1.44%)
NFLX   317.14 (+3.80%)
QQQ   293.62 (+0.09%)
AAPL   148.20 (+0.11%)
MSFT   254.74 (-0.16%)
META   120.16 (+1.74%)
GOOGL   101.18 (+0.19%)
AMZN   95.75 (-0.82%)
TSLA   195.18 (+0.25%)
NVDA   171.89 (+1.57%)
NIO   12.23 (-4.30%)
BABA   86.05 (-1.72%)
AMD   76.97 (-0.85%)
T   19.13 (-0.78%)
MU   55.49 (-3.75%)
CGC   3.75 (+3.59%)
F   14.03 (+0.94%)
GE   85.43 (-0.63%)
DIS   97.97 (+0.10%)
AMC   8.68 (+20.06%)
PYPL   78.41 (+0.00%)
PFE   50.85 (+1.44%)
NFLX   317.14 (+3.80%)
QQQ   293.62 (+0.09%)
AAPL   148.20 (+0.11%)
MSFT   254.74 (-0.16%)
META   120.16 (+1.74%)
GOOGL   101.18 (+0.19%)
AMZN   95.75 (-0.82%)
TSLA   195.18 (+0.25%)
NVDA   171.89 (+1.57%)
NIO   12.23 (-4.30%)
BABA   86.05 (-1.72%)
AMD   76.97 (-0.85%)
T   19.13 (-0.78%)
MU   55.49 (-3.75%)
CGC   3.75 (+3.59%)
F   14.03 (+0.94%)
GE   85.43 (-0.63%)
DIS   97.97 (+0.10%)
AMC   8.68 (+20.06%)
PYPL   78.41 (+0.00%)
PFE   50.85 (+1.44%)
NFLX   317.14 (+3.80%)

Eton Pharmaceuticals - ETON Stock Forecast, Price & News

$3.05
+0.03 (+0.99%)
(As of 12/1/2022 01:44 PM ET)
Add
Compare
Today's Range
$3.01
$3.05
50-Day Range
$2.02
$3.11
52-Week Range
$1.95
$4.78
Volume
400 shs
Average Volume
69,036 shs
Market Capitalization
$77.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Eton Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
232.2% Upside
$10.00 Price Target
Short Interest
Bearish
2.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$21,000 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.44) to $0.01 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

541st out of 1,047 stocks

Pharmaceutical Preparations Industry

253rd out of 512 stocks

ETON stock logo

About Eton Pharmaceuticals (NASDAQ:ETON) Stock

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Receive ETON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ETON Stock News Headlines

Eton Pharmaceuticals, Inc. (ETON)
Eton Pharmaceuticals Q2 2022 Earnings Preview
See More Headlines
Receive ETON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ETON Company Calendar

Last Earnings
11/10/2022
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/15/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ETON
Fax
N/A
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+227.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-1,960,000.00
Pretax Margin
-47.19%

Debt

Sales & Book Value

Annual Sales
$21.83 million
Book Value
$0.44 per share

Miscellaneous

Free Float
22,780,000
Market Cap
$77.17 million
Optionable
Not Optionable
Beta
1.40

Key Executives

  • Mr. Sean E. BrynjelsenMr. Sean E. Brynjelsen (Age 50)
    Pres, CEO & Director
    Comp: $692.12k
  • Mr. James R. Gruber CPA (Age 50)
    CFO, Treasurer & Sec.
  • Mr. David Krempa
    Sr. VP of Bus. Devel. & Investor Relations
  • Ms. Ingrid Hoos
    Sr. VP of Regulatory Affairs
  • Mr. Kevin Guthrie
    Exec. VP of Commercial Operations
  • Mr. Scott Grossenbach
    VP of Sales & Marketing













ETON Stock - Frequently Asked Questions

Should I buy or sell Eton Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ETON shares.
View ETON analyst ratings
or view top-rated stocks.

What is Eton Pharmaceuticals' stock price forecast for 2023?

1 brokers have issued twelve-month target prices for Eton Pharmaceuticals' stock. Their ETON share price forecasts range from $10.00 to $10.00. On average, they anticipate the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 231.1% from the stock's current price.
View analysts price targets for ETON
or view top-rated stocks among Wall Street analysts.

How have ETON shares performed in 2022?

Eton Pharmaceuticals' stock was trading at $4.29 on January 1st, 2022. Since then, ETON stock has decreased by 29.6% and is now trading at $3.02.
View the best growth stocks for 2022 here
.

When is Eton Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 15th 2023.
View our ETON earnings forecast
.

How were Eton Pharmaceuticals' earnings last quarter?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) released its quarterly earnings results on Thursday, November, 10th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.03. The business earned $3.22 million during the quarter, compared to analysts' expectations of $3 million. Eton Pharmaceuticals had a negative net margin of 47.19% and a negative trailing twelve-month return on equity of 64.18%.

What other stocks do shareholders of Eton Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eton Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Myovant Sciences (MYOV), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC) and Moderna (MRNA).

When did Eton Pharmaceuticals IPO?

(ETON) raised $22 million in an initial public offering on Wednesday, November 14th 2018. The company issued 3,600,000 shares at $6.00 per share. National Securities Corporation served as the underwriter for the IPO.

What is Eton Pharmaceuticals' stock symbol?

Eton Pharmaceuticals trades on the NASDAQ under the ticker symbol "ETON."

Who are Eton Pharmaceuticals' major shareholders?

Eton Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.66%), Westside Investment Management Inc. (1.87%), Paradigm Capital Management Inc. NY (1.19%), State Street Corp (0.28%), Citadel Advisors LLC (0.08%) and Virtu Financial LLC (0.07%). Insiders that own company stock include Harrow Health, Inc, Opaleye Management Inc, Pharmaceutical Co Ltd Takeda and Sean Brynjelsen.
View institutional ownership trends
.

How do I buy shares of Eton Pharmaceuticals?

Shares of ETON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eton Pharmaceuticals' stock price today?

One share of ETON stock can currently be purchased for approximately $3.02.

How much money does Eton Pharmaceuticals make?

Eton Pharmaceuticals (NASDAQ:ETON) has a market capitalization of $76.41 million and generates $21.83 million in revenue each year. The company earns $-1,960,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.

How can I contact Eton Pharmaceuticals?

Eton Pharmaceuticals' mailing address is 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010. The official website for the company is www.etonpharma.com. The company can be reached via phone at (847) 787-7361 or via email at investorrelations@etonpharma.com.

This page (NASDAQ:ETON) was last updated on 12/1/2022 by MarketBeat.com Staff